Eupraxia Pharmaceuticals Files 6-K with Financial Statements
Ticker: EPRX · Form: 6-K · Filed: May 8, 2024 · CIK: 1581178
Sentiment: neutral
Topics: financial-statements, reporting
TL;DR
Eupraxia Pharma dropped its latest financials via a 6-K, check it for the numbers.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 8, 2024, incorporating by reference its Consolidated Financial Statements. The company is incorporated in Canada and its fiscal year ends on December 31. This filing is related to its ongoing reporting requirements.
Why It Matters
This filing provides updated financial information for Eupraxia Pharmaceuticals Inc., which is crucial for investors to assess the company's financial health and performance.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not introduce new risks.
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Registrant
- 001-41923 (company) — SEC File Number
- 201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4 (company) — Principal Executive Offices Address
- May 8, 2024 (date) — Filing Date
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
When was this filing made?
The filing was made on May 8, 2024.
What is the company's principal executive office location?
The company's principal executive offices are located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Which registration statements does this filing incorporate by reference?
Exhibits 99.1 and 99.2 of this Form 6-K are incorporated by reference into the registrant's Registration Statement on Form F-10 (File No. 333-276586) and the registrant's Registration Statement on Form S-8 (File No. 333-278534).
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 256 words · 1 min read · ~1 pages · Grade level 9.5 · Accepted 2024-05-08 17:05:51
Filing Documents
- d832262d6k.htm (6-K) — 11KB
- d832262dex991.htm (EX-99.1) — 350KB
- d832262dex992.htm (EX-99.2) — 311KB
- d832262dex993.htm (EX-99.3) — 32KB
- d832262dex994.htm (EX-99.4) — 12KB
- d832262dex995.htm (EX-99.5) — 12KB
- g832262g0504071829971.jpg (GRAPHIC) — 13KB
- g832262g0504105925763.jpg (GRAPHIC) — 6KB
- 0001193125-24-134333.txt ( ) — 754KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: May 8, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer